Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS

Richard Lemal (1) , Guillemette Fouquet , Louis Terriou (2) , Mélanie Vaes , Cristina Bulai Livideanu , Laurent Frenzel , Stéphane Barete , Danielle Canioni , Ludovic Lhermitte , Julien Rossignol , Michel Arock , Patrice Dubreuil , Olivier Lortholary , Olivier Hermine

1 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias
2 LIRIC - Lille Inflammation Research International Center - U 995

Domains: Hematology

Richard Lemal, Guillemette Fouquet, Louis Terriou, Mélanie Vaes, Cristina Bulai Livideanu, et al.. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. Journal of Allergy and Clinical Immunology: In Practice, 2019, 7 (7), pp.2387-2395.e3. ⟨10.1016/j.jaip.2019.03.039⟩. ⟨hal-02299382⟩